Habil F Khorakiwala

The pharmaceutical industry did suffer some set back with sales declining about 10-12 percent since demonetisation. However, Habil F Khorakiwala, Founder, Chairman & Group CEO of Wockhardt feels the impact will last only until January at the most as cash availability is improving.

See double-digit sales growth across markets in FY17: Wockhardt

Habil F Khorakiwala, founder, chairman and group CEO of Wockhardt says the company has replied to US food and drug administration (FDA) on issues related to its L1, Waluj and Shendra facilities and although a few issues are pending, he hopes it will be resolved soon

Will take 2-2.5 yrs for phase-3 clinical trails: Wockhardt

The QIDP status will allow fast tracking of the drug application from the USFDA and 5-year extension for the drug patents in the US.

India's pharma industry seeing rapid growth: Wockhardt

According to Habil F Khorakiwala, India is becoming a research and manufacturing hub for global pharmaceutical generic companies and the Indian companies that have well established base in the generic space like Stride transaction are getting high valuation.

Taking corrrective measures on regulatory issues: Wockhardt

Paracetamol is a very important anti-fever and painkiller, which has a large domestic production. India consumes about 10,000 tonnes of the drug in one year, says Dr Habil F Khorakiwala of Wockhardt .

Wockhardt up 5% as Khorakiwala Holdings release pledge

Wockhardt's promoter Khorakiwala Holdings & Investments Pvt Ltd released pledge on its 6.97 crore equity shares (63.62 percent) on Wednesday. Now only 4.4 lakh shares or 0.4 percent equity of Habil F Khorakiwala is pledged.

Wockhardt at record high, rises 16% in 6 consecutive days

Healthcare firm Wockhardt gained for the sixth consecutive session on Tuesday, hitting a new record high of Rs 2,166.05.